The role of targeted therapy and biomarkers in breast cancer treatment (Q38018259)

27 August 2017

title

The role of targeted therapy and biomarkers in breast cancer treatment (English)

1 reference

27 August 2017

0 references

8

Hope S Rugo

1 reference

27 August 2017

Alison T Stopeck

1

1 reference

27 August 2017

Ursa Brown-Glaberman

2

1 reference

27 August 2017

Hong Yuen Wong

3

1 reference

27 August 2017

Ben Ho Park

4

1 reference

27 August 2017

Sara E Barnato

5

1 reference

27 August 2017

William J Gradishar

6

1 reference

27 August 2017

Clifford A Hudis

7

1 reference

27 August 2017

publication date

13 June 2012

1 reference

Clinical & Experimental Metastasis

27 August 2017

published in

1 reference

27 August 2017

volume

29

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

807-819

1 reference

https://scigraph.springernature.com/pub.10.1007/s10585-012-9496-y

27 August 2017

exact match

0 references

cites work

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

KRAS mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Circulating mutant DNA to assess tumor dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Triple-negative breast cancer: an unmet medical need

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Molecular stratification of triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Dissecting the heterogeneity of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

A compact VEGF signature associated with distant metastases and poor outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Triple-negative breast cancer: role of antiangiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Triple-negative breast cancer: disease entity or title of convenience?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Notch signaling and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

A monoclonal antibody against human Notch1 ligand-binding domain depletes subpopulation of putative breast cancer stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Leukocyte composition of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Detecting an overall survival benefit that is derived from progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Circulating endothelial cells as biomarkers in clinical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Tumor angiogenesis: molecular pathways and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Vascular endothelial growth factor (VEGF) signaling in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Tumor-induced lymphangiogenesis: a target for cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Antiangiogenic strategies in breast cancer management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Biomarkers of response and resistance to antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

Serum Soluble Vascular Cell Adhesion Molecule-1: Role as a Surrogate Marker of Angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-012-9496-Y

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

21 January 2018

1 reference

12 December 2020

Effect of anti-DR5 and chemotherapy on basal-like breast cancer

1 reference

12 December 2020

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer

1 reference

12 December 2020

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

1 reference

12 December 2020

Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients

1 reference

12 December 2020

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

12 December 2020

Resting and activated endothelial cells are increased in the peripheral blood of cancer patients

1 reference

12 December 2020

Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth

1 reference

12 December 2020

Interaction of tumor cells and lymphatic vessels in cancer progression

1 reference

12 December 2020

10.1007/S10585-012-9496-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1040153979

0 references

1 reference